Clinical Efficacy and Quality of Life Study of Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

HUANG Yunyun; WU Qiu; XU Jingjing

doi:10.13919/j.issn.2095-6274.ZHJY202406027

Abstract：Objective To investigate the clinical efficacy of tyrosine kinase inhibitors(TKIs)in the treat-ment of chronic myeloid leukemia(CML)and their impact on quality of life.Methods 78 CML patients treated at Qianxinan Prefecture People's Hospital from June 2020 to June 2023 were selected and divided into the control group(n=34)and the observation group(n=34).The control group received sunitinib treatment,while the observa-tion group received flumatinib treatment.Treatment efficacy,recurrence rates,pre-and post-treatment quality of life,and incidence of adverse reactions were compared between the two groups.Results The observation group showed higher rates of early molecular response(EMR)and major molecular response(MMR)at 3 and 6 months of treatment compared to the control group(EMR:75％vs 60％,MMR:65％vs50％,P＜0.05).The recurrence rate in the observation group was notably lower compared to the control group(10％vs 25％,P＜0.05).After 6 months of treatment,there was no significant difference in SF-36 quality of life scores between the two groups(P＞0.05).The incidence of gastrointestinal adverse reactions in the observation group was higher than that in the control group(30％vs 15％,P＜0.05),but the incidences of rash and edema were lower in the observation group than those in the control group(rash:5％vs 20％,edema:10％vs 25％,P＜0.05).There was no significant difference in he-matologic adverse reactions between the two groups(P＞0.05).Conclusion Flumatinib is superior to sunitinib in treating CML patients,particularly in reducing recurrence rates.Both medications can improve patients'quality of life,though each has associated adverse reactions.Long-term follow-up studies are needed to comprehensively evaluate their long-term efficacy and safety.